Boehringer Ingelheim
This website is for UK Healthcare Professionals. If you are a patient or member of the public please visit our public website here
Find adverse event reporting information at the bottom of this page
Contact
Boeringer Ingelheim Logo
Boeringer Ingelheim
Boeringer Ingelheim Logo
Boeringer Ingelheim
Boeringer Ingelheim Logo
Boeringer Ingelheim
  • Diseases
    Diseases

    • Diseases
    • Asthma
    • Chronic Heart Failure (CHF) Opens in new tab
    • Chronic Kidney Disease (CKD) Opens in new tab
    • COPD
    • Idiopathic Pulmonary Fibrosis (IPF)
    • Progressive Pulmonary Fibrosis (PPF)
    • Stroke
    • Type 2 Diabetes
  • Products
    Products

    • Products
    • Empagliflozin
    • Linagliptin
    • METALYSE 25 mg (tenecteplase)
    • OFEV® (nintedanib)
    • SPIOLTO® Respimat® (tiotropium/olodaterol)
    • SPIRIVA® Respimat® (tiotropium)
  • Resources
    Resources

    • Resources
      • Healthcare Professional Resources
      • Cardio Renal Metabolism
      • Respiratory
  • Click here to join
    our mailing list to hear
    news & updates about our products
    Opens in new tab
  • Find adverse event reporting information at the bottom of this page
  • Contact
Boeringer Ingelheim

Accessibility Statement for Boehringer Ingelheim websites

Boehringer Ingelheim is committed to providing a website that is accessible to the widest possible audience, regardless of technology or ability. We are actively working to increase the accessibility and usability of our website and in doing so adhere to many of the available standards and guidelines. These guidelines explain how to make web content more accessible for people with disabilities. Conformance with these guidelines will help make the web more user friendly for all people. We are continually seeking out solutions that will bring all areas of the Site up to the same level of overall web accessibility.

Multimedia elements: Images, video and audio files

Alternative and short descriptive  texts are available for all multimedia and non-text content. A simplified version of the Site is also available, displaying a page with descriptive texts in the place of all images and videos. All videos and multimedia give a size indication, so that downloading time can be estimated. If software is required to view the videos, a plug in download link will be posted. An HTML substitute for Flash Player will also be provided for future videos. All videos will be presented with player software which enables the user to play, pause, stop forward and rewind the video. Live web casts will  be archived after broadcasting to be available for a later viewing. No flashing content will be provided.

Presentation of Content and Layout

There is a strict separation of content and layout via the proper use of HTML and CSS (Cascading Style Sheet). Layout tables are avoided where possible.

We are focusing on structuring items, making it possible to scan through a document and giving air to long texts. This includes:

  • chapter starting pages that show which content is provided within subchapters

  • consequent use of headlines, short introduction text on every webpage and sub headlines

  • tables and bullet list for helping readers

  • graphics for complex content.

We try to offer a clear navigation structure that helps you to find the content you are looking for in an easy and quick way.

Links contain title attributes which describe content and make sense out of context.

The use of short sentences and paragraphs and multiple entry points to additional information sources e.g. via teaser elements and related content areas will make it easier to comprehend the content.

In the meantime, should you experience any difficulty in accessing the Boehringer Ingelheim website, please do not hesitate to contact us via communications.bra@boehringer-ingelheim.com.

PC-GB-110797 V2 | March 2026

Reporting adverse events

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Boehringer Ingelheim Drug Safety on 0800 328 1627 (freephone).

Please be aware that this website contains promotional information about Boehringer Ingelheim medicines and services. Some of this may not be directly relevant to your scope of practice and it is your own decision whether you choose to view this information.

  1. Home
  2. Accessibility Statement
  • Contact Us
  • Cookie Policy
  • Privacy Policy
  • Sitemap
  • Terms of Use
  • Accessibility Statement

Boehringer Ingelheim Logo
Boehringer Ingelheim

This information is for UK Healthcare Professionals only. Products discussed herein may have different labelling in different countries. 
Use of this site is subject to the Internet Site Legal Notices and Disclaimers and Privacy Notice.

Copyright © 2021-2026 Boehringer Ingelheim, Inc. All rights reserved. PC-GB-110791 V3 May 2026.